DNA-protein cross-links emerge as major contributors to chemotherapeutic cytotoxicity at physiological equitoxic doses

Abstract Chemotherapeutic drugs induce DNA damage, including double-strand breaks (DSBs), interstrand cross-links (ICLs), and DNA-protein cross-links (DPCs), to inhibit cancer cell proliferation. Understanding the relative contributions of these damages is essential for optimizing therapeutic strate...

Full description

Saved in:
Bibliographic Details
Main Authors: Mahmoud I. Shoulkamy, Tareg Omer Mohammed, Hiroshi Ide, Toshiaki Nakano
Format: Article
Language:English
Published: Nature Portfolio 2025-07-01
Series:Scientific Reports
Subjects:
Online Access:https://doi.org/10.1038/s41598-025-06705-3
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849769315700572160
author Mahmoud I. Shoulkamy
Tareg Omer Mohammed
Hiroshi Ide
Toshiaki Nakano
author_facet Mahmoud I. Shoulkamy
Tareg Omer Mohammed
Hiroshi Ide
Toshiaki Nakano
author_sort Mahmoud I. Shoulkamy
collection DOAJ
description Abstract Chemotherapeutic drugs induce DNA damage, including double-strand breaks (DSBs), interstrand cross-links (ICLs), and DNA-protein cross-links (DPCs), to inhibit cancer cell proliferation. Understanding the relative contributions of these damages is essential for optimizing therapeutic strategies. To achieve physiologically relevant conditions, we determined the LD20 for four classes of chemotherapeutic agents and treated HeLa cells accordingly. Topoisomerase inhibitors (CPT, ETO) primarily induced DSBs and DPCs, whereas platinum-based agents (CisPt, OXA) predominantly caused DPCs and ICLs. The DNMT inhibitor AzadC was strongly associated with DPC formation. Although both L-PAM and MMC are bifunctional alkylating agents, their cytotoxic mechanisms differed; L-PAM induced DSBs, DPCs, and ICLs, while MMC primarily caused ICLs. DPCs were consistently detected across all drug treatments except MMC, with a half-life of 4.7 to 8.4 h, suggesting their prolonged impact on cytotoxicity. To assess apoptosis induction, we performed Annexin-V assays, which revealed significant apoptotic responses in all treated cells. CPT exhibited the highest proportion of early apoptotic cells (~ 80%) at 24 h, with all drug treatments shifting from early to late apoptosis over time. By 48 h, late apoptotic fractions exceeded 60% in CPT-, ETO-, and AzadC-treated cells. These findings highlight the critical role of DPCs in chemotherapeutic cytotoxicity and suggest that targeting apoptotic pathways could enhance cancer treatment efficacy.
format Article
id doaj-art-5f90f91189364939bab158301f2eaec5
institution DOAJ
issn 2045-2322
language English
publishDate 2025-07-01
publisher Nature Portfolio
record_format Article
series Scientific Reports
spelling doaj-art-5f90f91189364939bab158301f2eaec52025-08-20T03:03:27ZengNature PortfolioScientific Reports2045-23222025-07-0115111410.1038/s41598-025-06705-3DNA-protein cross-links emerge as major contributors to chemotherapeutic cytotoxicity at physiological equitoxic dosesMahmoud I. Shoulkamy0Tareg Omer Mohammed1Hiroshi Ide2Toshiaki Nakano3WPI Nano Life Science Institute (WPI-Nano LSI), Kanazawa UniversityWPI Nano Life Science Institute (WPI-Nano LSI), Kanazawa UniversityProgram of Mathematical and Life Sciences, Department of Integrated Sciences for Life, Graduate School of Integrated Sciences for Life, Hiroshima UniversityProgram of Mathematical and Life Sciences, Department of Integrated Sciences for Life, Graduate School of Integrated Sciences for Life, Hiroshima UniversityAbstract Chemotherapeutic drugs induce DNA damage, including double-strand breaks (DSBs), interstrand cross-links (ICLs), and DNA-protein cross-links (DPCs), to inhibit cancer cell proliferation. Understanding the relative contributions of these damages is essential for optimizing therapeutic strategies. To achieve physiologically relevant conditions, we determined the LD20 for four classes of chemotherapeutic agents and treated HeLa cells accordingly. Topoisomerase inhibitors (CPT, ETO) primarily induced DSBs and DPCs, whereas platinum-based agents (CisPt, OXA) predominantly caused DPCs and ICLs. The DNMT inhibitor AzadC was strongly associated with DPC formation. Although both L-PAM and MMC are bifunctional alkylating agents, their cytotoxic mechanisms differed; L-PAM induced DSBs, DPCs, and ICLs, while MMC primarily caused ICLs. DPCs were consistently detected across all drug treatments except MMC, with a half-life of 4.7 to 8.4 h, suggesting their prolonged impact on cytotoxicity. To assess apoptosis induction, we performed Annexin-V assays, which revealed significant apoptotic responses in all treated cells. CPT exhibited the highest proportion of early apoptotic cells (~ 80%) at 24 h, with all drug treatments shifting from early to late apoptosis over time. By 48 h, late apoptotic fractions exceeded 60% in CPT-, ETO-, and AzadC-treated cells. These findings highlight the critical role of DPCs in chemotherapeutic cytotoxicity and suggest that targeting apoptotic pathways could enhance cancer treatment efficacy.https://doi.org/10.1038/s41598-025-06705-3DNA damageChemotherapeutic drugsCytotoxicityEquitoxic doseCancer therapies
spellingShingle Mahmoud I. Shoulkamy
Tareg Omer Mohammed
Hiroshi Ide
Toshiaki Nakano
DNA-protein cross-links emerge as major contributors to chemotherapeutic cytotoxicity at physiological equitoxic doses
Scientific Reports
DNA damage
Chemotherapeutic drugs
Cytotoxicity
Equitoxic dose
Cancer therapies
title DNA-protein cross-links emerge as major contributors to chemotherapeutic cytotoxicity at physiological equitoxic doses
title_full DNA-protein cross-links emerge as major contributors to chemotherapeutic cytotoxicity at physiological equitoxic doses
title_fullStr DNA-protein cross-links emerge as major contributors to chemotherapeutic cytotoxicity at physiological equitoxic doses
title_full_unstemmed DNA-protein cross-links emerge as major contributors to chemotherapeutic cytotoxicity at physiological equitoxic doses
title_short DNA-protein cross-links emerge as major contributors to chemotherapeutic cytotoxicity at physiological equitoxic doses
title_sort dna protein cross links emerge as major contributors to chemotherapeutic cytotoxicity at physiological equitoxic doses
topic DNA damage
Chemotherapeutic drugs
Cytotoxicity
Equitoxic dose
Cancer therapies
url https://doi.org/10.1038/s41598-025-06705-3
work_keys_str_mv AT mahmoudishoulkamy dnaproteincrosslinksemergeasmajorcontributorstochemotherapeuticcytotoxicityatphysiologicalequitoxicdoses
AT taregomermohammed dnaproteincrosslinksemergeasmajorcontributorstochemotherapeuticcytotoxicityatphysiologicalequitoxicdoses
AT hiroshiide dnaproteincrosslinksemergeasmajorcontributorstochemotherapeuticcytotoxicityatphysiologicalequitoxicdoses
AT toshiakinakano dnaproteincrosslinksemergeasmajorcontributorstochemotherapeuticcytotoxicityatphysiologicalequitoxicdoses